Palazestrant

CAS No. 2092925-89-6

Palazestrant( —— )

Catalog No. M36480 CAS No. 2092925-89-6

Palazestrant (OP-1250) is an orally available and highly potent estrogen receptor antagonist and selective ER degrader with antitumor activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 445 Get Quote
5MG 686 Get Quote
10MG 938 Get Quote
25MG 1398 Get Quote
50MG 1822 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Palazestrant
  • Note
    Research use only, not for human use.
  • Brief Description
    Palazestrant (OP-1250) is an orally available and highly potent estrogen receptor antagonist and selective ER degrader with antitumor activity.
  • Description
    Palazestrant is an antiestrogen and antineoplastic agent. Palazestrant in combination with a HER2 inhibitor, works on ER+/HER2+ cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Endocrinology/Hormones
  • Target
    Estrogen Receptor/ERR
  • Recptor
    Estrogen/progestogen Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2092925-89-6
  • Formula Weight
    449.6
  • Molecular Formula
    C28H36FN3O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(C(C)(C)F)N1[C@@H](C2=C(C=3C(N2)=CC=CC3)C[C@H]1C)C4=CC=C(OC5CN(CCC)C5)C=C4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Harmon CL, et al. Methods of treating estrogen receptor-associated diseases such as ER+/HER2+ cancer using an estrogen receptor antagonist: World Intellectual Property Organization, WO2023283329. 2023-01-12.
molnova catalog
related products
  • Enclomiphene citrate

    Enclomiphene citrate((E)-Clomifene, cis-Clomifene, RMI-16289, ICI-46476)?is a nonsteroidal selective estrogen receptor modulator (SERM) that is under development for the treatment of male hypogonadism.

  • Giredestrant tartrat...

    Giredestrant tartrate (Estrogen receptor antagonist 1) is a novel, orally active, selective and effective non-steroidal estrogen receptor antagonist.

  • Gestrinone

    Gestrinone is a synthetic androgen receptor agonist and ER and progesterone receptor antagonist used to treat endometriosis. It inhibits leiomyoma cells with an IC50 of 43.67 μM.